Guardant Health, Inc. (NASDAQ:GH) Shares Purchased by SWS Partners

SWS Partners boosted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 44.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 120,888 shares of the company’s stock after purchasing an additional 37,126 shares during the quarter. Guardant Health makes up approximately 1.1% of SWS Partners’ holdings, making the stock its 20th largest holding. SWS Partners owned about 0.10% of Guardant Health worth $3,693,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. JNBA Financial Advisors bought a new position in shares of Guardant Health during the third quarter worth about $26,000. R Squared Ltd acquired a new stake in Guardant Health during the fourth quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new position in Guardant Health during the 3rd quarter worth approximately $34,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health in the 4th quarter worth approximately $43,000. Finally, Nisa Investment Advisors LLC grew its position in shares of Guardant Health by 168.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock worth $79,000 after acquiring an additional 2,153 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Canaccord Genuity Group raised their price objective on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Guggenheim restated a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Stifel Nicolaus boosted their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Piper Sandler increased their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Barclays assumed coverage on Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price for the company. Nineteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $48.21.

Guardant Health Trading Down 4.3 %

Guardant Health stock opened at $40.74 on Tuesday. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The stock has a market cap of $5.03 billion, a price-to-earnings ratio of -11.44 and a beta of 1.32. The company’s 50-day moving average price is $41.09 and its two-hundred day moving average price is $32.01.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 2,668 shares of company stock worth $95,208. 5.50% of the stock is owned by company insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.